Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

The Multi-Heart Plate: a human engineered mini-heart platform for functional cardiac disease modelling and drug testing

Objectif

Cardiovascular diseases remain a leading cause of mortality worldwide, yet drug development is hampered by the lack of predictive human models that capture cardiac function. In particular, diastolic dysfunction and heart failure with preserved ejection fraction represent major unmet medical needs, partly because current preclinical models inadequately reproduce human cardiac physiology. This HEARTPUMP project aims to explore the innovation potential of the Multi-Heart Plate (MHP), a novel human stem cell-based platform developed in the ERC Advanced Grant HEART2BEAT. The MHP consists of miniature engineered cardiac chambers capable of pumping fluid and generating quantitative functional readouts such as cardiac output, ejection fraction and relaxation kinetics. This enables direct assessment of cardiac performance and drug responses in a physiologically relevant human model. HEARTPUMP will combine technical validation and commercial feasibility activities. Technically, we will demonstrate the reproducibility and robustness of the platform, develop and validate a diastolic dysfunction disease model, and establish a drug screening portfolio to benchmark predictive performance against existing models. Workflow optimization, including automated data analysis and assay standardization will further improve scalability and usability for drug discovery. In parallel, we will engage with pharmaceutical and biotechnology companies and contract research organizations to assess industry requirements and obtain early feedback. Intellectual property strategy and market analysis will be conducted with technology transfer experts to evaluate commercial opportunities and guide the development of a business plan. Together, these activities will demonstrate the technical and commercial feasibility of the MHP platform and establish the basis for its translation into cardiovascular drug discovery, potentially through creation of a spin-out company or alternative commercialization pathways.

Champ scientifique (EuroSciVoc)

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Programme(s)

Thème(s)

Régime de financement

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2026-POC

Voir tous les projets financés au titre de cet appel

Institution d’accueil

UNIVERSITEIT TWENTE
Contribution nette de l'UE
€ 150 000,00
Adresse
DRIENERLOLAAN 5
7522 NB Enschede
Pays-Bas
Région
Oost-Nederland Overijssel Twente
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
Aucune donnée

Bénéficiaires (1)